TCRβ diversity and clone tracking. (A) Simpson clonality within Treg (blue) and CD4⁺ Tcon (red) of dose level C patients. Diversity measurements were assessed within the Treg DLI product (DLI) and at baseline, week 8 (W8), 6 months (6M), and 1 year (1Y) after Treg DLI infusion and initiation of LD IL-2. (B) Percent of the 1000 most prevalent DLI-derived Treg and CD4⁺ Tcon clones that were detected at week 8 (W8) within each patient at each dose level. Dots depict individual patients. The lines represent the median value for each dose level. (C) Persistence of the top 1000 DLI-derived Treg (blue) and CD4⁺ Tcon (red) clones at 6 months (6M) and 1 year (1Y) after IL-2 initiation in patients receiving extended IL-2 therapy. Box plots depict the 75th percentile, median, and 25th percentile values; whiskers represent maximum and minimum values except for outliers (>1.5 times the interquartile range above Q3 or below Q1). Bar graphs represent median values; whiskers represent the interquartile range. The number of patients evaluated at each time point is indicated at the bottom of the image. Two-sided Wilcoxon signed-rank test was used to assess significance.